Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 14c
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $252.35 +1.61%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $2.44, $0.14 better than the analyst estimate of $2.30. Revenue for the quarter came in at $328.1 million versus the consensus estimate of $319.74 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna shares tumble on weak full-year revenue guidance
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- TD Cowen Reiterates Buy Rating on NVIDIA (NVDA), 'unlikely to move significantly on earnings'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
